Royalty Pharma plc Stock News

Shares of Royalty Pharma plc (NASDAQ: RPRX) are up about 4.0% this morning after Warren Buffets Berkshire Hathaway announced a $475 million investment in the U.S. company that buys drug royalties. Other changes to Berkshires investment portfolio in Q3 The regulatory filing late on Monday that detailed where Berkshire was invested as of September 30th [] The post Heres what Warren Buffet was buying and selling in Q3 appeared first on Invezz.

The stocks making the biggest moves in premarket trading include Rackspace Technology, Axon Enterprise, Royalty Pharma, and more.

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial) ( BRK.B , Financial) published its third-quarter 13F filing earlier this week, reporting U.S. equity position changes durin

Royalty Pharma plc (NASDAQ:RPRX) Equities research analysts at Truist Securiti reduced their Q4 2021 earnings per share estimates for Royalty Pharma in a report issued on Wednesday, November 10th. Truist Securiti analyst G. Fraser now expects that the biopharmaceutical company will post earnings per share of $0.80 for the quarter, down from their previous []

Related Stocks: CVX , RPRX , FND , MRK , LBTYK , OGN ,

The legendary investor built a $475 million stake in Royalty Pharma, owning more than 13,000 shares at the end of September.

Warren Buffett (Trades, Portfolio)'s multibillion-dollar conglomerate, Berkshire Hathaway Inc. ( BRK.A , Financial)( BRK.B , Financial), disclosed its equity portfolio for the third quarter of 2021 on

The famed investor's company also exited Merck and trimmed several holdings including Visa, Mastercard, and AbbVie.

Royalty Pharma plc (RPRX) CEO Pablo Legorreta on Q3 2021 Results - Earning Call Transcript

Royalty Pharma (RPRX) delivered earnings and revenue surprises of 5.80% and 3.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

RPRX buys royalties of high-profile assets.

NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter of 2021 financial results on Wednesday, November 10, 2021 before the

NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2021 of $0.17 per Class A ordin

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after